» Articles » PMID: 34644288

Clinical Diversity and Treatment Results in Tegumentary Leishmaniasis: A European Clinical Report in 459 Patients

Abstract

Background: Cutaneous leishmaniasis (CL) is frequent in travellers and can involve oro-nasal mucosae. Clinical presentation impacts therapeutic management.

Methodology: Demographic and clinical data from 459 travellers infected in 47 different countries were collected by members of the European LeishMan consortium. The infecting Leishmania species was identified in 198 patients.

Principal Findings: Compared to Old World CL, New World CL was more frequently ulcerative (75% vs 47%), larger (3 vs 2cm), less frequently facial (17% vs 38%) and less frequently associated with mucosal involvement (2.7% vs 5.3%). Patients with mucosal lesions were older (58 vs 30 years) and more frequently immunocompromised (37% vs 3.5%) compared to patients with only skin lesions. Young adults infected in Latin America with L. braziliensis or L. guyanensis complex typically had an ulcer of the lower limbs with mucosal involvement in 5.8% of cases. Typically, infections with L. major and L. tropica acquired in Africa or the Middle East were not associated with mucosal lesions, while infections with L. infantum, acquired in Southern Europe resulted in slowly evolving facial lesions with mucosal involvement in 22% of cases. Local or systemic treatments were used in patients with different clinical presentations but resulted in similarly high cure rates (89% vs 86%).

Conclusion/significance: CL acquired in L. infantum-endemic European and Mediterranean areas displays unexpected high rates of mucosal involvement comparable to those of CL acquired in Latin America, especially in immunocompromised patients. When used as per recommendations, local therapy is associated with high cure rates.

Citing Articles

A rare case of lingual mucosal leishmaniasis caused by reactivation of Leishmania infantum infection.

Eggers Y, Holtfreter M, Muller-Stoever I, Mischlinger J, Hammacher A, Hemmerlein B BMC Infect Dis. 2025; 25(1):234.

PMID: 39966762 PMC: 11837717. DOI: 10.1186/s12879-025-10592-4.


Cutaneous leishmaniasis in sub-Saharan Africa: a systematic review of Leishmania species, vectors and reservoirs.

Blaizot R, Pasquier G, Kone A, Duvignaud A, Demar M Parasit Vectors. 2024; 17(1):318.

PMID: 39044228 PMC: 11267819. DOI: 10.1186/s13071-024-06381-8.


American Cutaneous Leishmaniasis: Imported cases in Berlin 2000-2023.

Lindner A, Castillo M, Wintel M, Martinez G, Richter J, Kurth F PLoS Negl Trop Dis. 2024; 18(7):e0012323.

PMID: 39008517 PMC: 11271916. DOI: 10.1371/journal.pntd.0012323.


Isolation and characterisation of Leishmania (Leishmania) infantum from cutaneous leishmaniasis patients in northeast Brazil.

Soares G, Barbosa G, Coelho A, Caetano G, de Azevedo C, Coelho A Mem Inst Oswaldo Cruz. 2024; 119:e240026.

PMID: 38985088 PMC: 11251414. DOI: 10.1590/0074-02760240026.


Leishmaniasis in otorhinolaryngology: an emerging disease and its relationship with anti-tumor necrosis factor-alpha drugs.

Penella A, Muntaner-Virgili C, Marcoval J, Gonzalez-Compta X, Mesalles-Ruiz M, Garcia Wagner M Eur Arch Otorhinolaryngol. 2024; 281(5):2739-2742.

PMID: 38453713 DOI: 10.1007/s00405-024-08569-1.


References
1.
Blum J, Lockwood D, Visser L, Harms G, Bailey M, Caumes E . Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health. 2013; 4(3):153-63. DOI: 10.1016/j.inhe.2012.06.004. View

2.
Boggild A, Caumes E, Grobusch M, Schwartz E, Hynes N, Libman M . Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis. J Travel Med. 2019; 26(8). PMC: 7353840. DOI: 10.1093/jtm/taz055. View

3.
Mosimann V, Neumayr A, Paris D, Blum J . Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review. Acta Trop. 2018; 182:246-250. DOI: 10.1016/j.actatropica.2018.03.016. View

4.
Salah A, Ben Messaoud N, Guedri E, Zaatour A, Alaya N, Bettaieb J . Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013; 368(6):524-32. DOI: 10.1056/NEJMoa1202657. View

5.
Sosa N, Pascale J, Jimenez A, Norwood J, Kreishman-Detrick M, Weina P . Topical paromomycin for New World cutaneous leishmaniasis. PLoS Negl Trop Dis. 2019; 13(5):e0007253. PMC: 6497224. DOI: 10.1371/journal.pntd.0007253. View